Biontech Se Stock Piotroski F Score
| BNTX Stock | USD 86.40 0.06 0.07% |
BioNTech | Piotroski F Score |
At this time, it appears that BioNTech's Piotroski F Score is Very Strong. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
9.0
Piotroski F Score - Very Strong
| Current Return On Assets | Positive |
| Change in Return on Assets | Increased |
| Cash Flow Return on Assets | Positive |
| Current Quality of Earnings (accrual) | Improving |
| Asset Turnover Growth | Increase |
| Current Ratio Change | Increase |
| Long Term Debt Over Assets Change | Lower Leverage |
| Change In Outstending Shares | Decrease |
| Change in Gross Margin | Increase |
BioNTech Piotroski F Score Drivers
The critical factor to consider when applying the Piotroski F Score to BioNTech is to make sure BioNTech is not a subject of accounting manipulations and runs a healthy internal audit department. So, if BioNTech's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if BioNTech's financial numbers are properly reported.
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.32 | 0.166 |
|
| |||||
| Total Current Liabilities | 1.3 B | 2.1 B |
|
| |||||
| Non Current Liabilities Total | 378.2 M | 689.9 M |
|
| |||||
| Total Assets | 24.2 B | 23 B |
|
| |||||
| Total Current Assets | 20.5 B | 19.5 B |
|
|
BioNTech SE F Score Driver Matrix
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between BioNTech's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards BioNTech in a much-optimized way.
Click cells to compare fundamentals
About BioNTech Piotroski F Score
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.Book Value Per Share |
|
BioNTech Current Valuation Drivers
We derive many important indicators used in calculating different scores of BioNTech from analyzing BioNTech's financial statements. These drivers represent accounts that assess BioNTech's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of BioNTech's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 2.8B | 6.4B | 15.7B | 34.3B | 23.0B | 24.1B | |
| Enterprise Value | 2.5B | 5.9B | 14.7B | 20.6B | 11.5B | 7.7B |
About BioNTech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioNTech SE's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioNTech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioNTech SE based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
BioNTech Investors Sentiment
The influence of BioNTech's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in BioNTech. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to BioNTech's public news can be used to forecast risks associated with an investment in BioNTech. The trend in average sentiment can be used to explain how an investor holding BioNTech can time the market purely based on public headlines and social activities around BioNTech SE. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
BioNTech's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for BioNTech's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average BioNTech's news discussions. The higher the estimated score, the more favorable is the investor's outlook on BioNTech.
BioNTech Implied Volatility | 48.79 |
BioNTech's implied volatility exposes the market's sentiment of BioNTech SE stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if BioNTech's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that BioNTech stock will not fluctuate a lot when BioNTech's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards BioNTech in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, BioNTech's short interest history, or implied volatility extrapolated from BioNTech options trading.
Pair Trading with BioNTech
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BioNTech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioNTech will appreciate offsetting losses from the drop in the long position's value.Moving together with BioNTech Stock
| 0.72 | VRTX | Vertex Pharmaceuticals Financial Report 6th of May 2024 | PairCorr |
Moving against BioNTech Stock
| 0.71 | RZLT | Rezolute Trending | PairCorr |
| 0.66 | NVO | Novo Nordisk AS Financial Report 2nd of May 2024 | PairCorr |
| 0.63 | MRK | Merck Company Earnings Call Next Week | PairCorr |
| 0.63 | INDP | Indaptus Therapeutics Financial Report 9th of May 2024 | PairCorr |
| 0.59 | CELC | Celcuity LLC Financial Report 20th of May 2024 | PairCorr |
The ability to find closely correlated positions to BioNTech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BioNTech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BioNTech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BioNTech SE to buy it.
The correlation of BioNTech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BioNTech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BioNTech SE moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BioNTech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out BioNTech Altman Z Score, BioNTech Correlation, BioNTech Valuation, as well as analyze BioNTech Alpha and Beta and BioNTech Hype Analysis. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Complementary Tools for BioNTech Stock analysis
When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |
Is BioNTech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioNTech. If investors know BioNTech will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioNTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.80) | Earnings Share 4.08 | Revenue Per Share 15.873 | Quarterly Revenue Growth (0.65) | Return On Assets 0.0262 |
The market value of BioNTech SE is measured differently than its book value, which is the value of BioNTech that is recorded on the company's balance sheet. Investors also form their own opinion of BioNTech's value that differs from its market value or its book value, called intrinsic value, which is BioNTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioNTech's market value can be influenced by many factors that don't directly affect BioNTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioNTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.